Science and Technology - Minutes of Evidence [Back to Report]

---

Here you can browse the Minutes of Evidence which were ordered by the House of Commons to be printed 1 July 1998.

MINUTES OF EVIDENCE

TAKEN BEFORE THE SCIENCE AND TECHNOLOGY COMMITTEE

WEDNESDAY 1 JULY 1998

---

Members present:

Dr Michael Clark, in the Chair

Mr Nigel Beard	Mrs Jacqui Lait
Dr Ian Gibson	Dr Desmond Turner
Dr Lynne Jones	Dr Alan W Williams
Mr Nigel Jones

---

CONTENTS

(The following memorandum was submitted on 8 June, prior to the Committee's inquiry)

Memorandum submitted by British Biotech plc

INTRODUCTION

CHRONOLOGY OF RELEVANT EVENTS

FURTHER INFORMATION

OTHER MATTERS

CONCLUSION

Additional memorandum submitted by British Biotech plc

Letter to the Clerk of the Committee from Mr Keith McCullagh, Chief Executive Officer, British Biotech plc

SELECT COMMITTEE—WEDNESDAY 1 JULY 1998

INTRODUCTION

SECTION A: REGULATORY AND CLINICAL PROCEDURES

SECTION B: FUNDING AND RELATED ISSUES

SECTION C: BRITISH BIOTECH MATTERS

ANNEX A

Memorandum to Peder Jensen from Andy Millar

REDUNDANCY

ANNEX 1

CHRONOLOGY OF EVENTS

INTRODUCTION

FURTHER INFORMATION

ANNEX 2

KEITH MCCULLAGH Chief Executive Officer

CAREER SUMMARY

Examination of Witnesses

DR KEITH MCCULLAGH, Chief Executive, and DR PEDER JENSEN, Development Director and Chief Medical Officer, British Biotech plc, were examined.

Question Number

1 - 19

20 - 39

40 - 59

60 - 79

80 - 99

100 - 105

Memorandum submitted by Andrew Millar

Annex A

An open letter

Annex B

Chronology of BB events by project

Annex C

Schedule of documents returned to British Biotech by Dr A W Millar on 28/5/98

Annex D

Memo to file 3 February 1995

Memo to file (15/2/95)

Note to file 17 May 1995

Note to Annex E

Attached memos about licensing deals

Annex F

Faxed statement from Andy Millar re unblinding of Zacutex study 215 7 May 1998

Faxed summary from Andy Millar re unblinding of studies 7 May 1998

Annex G

Peter J Lewis

Annex H

Memorandum from Andrew Millar at British Biotech

Annex I

Memorandum

Annex L

John Raisman, British Biotech

British Biotech Plc ("the Company")

BRITISH BIOTECH PLC ("the Company")

Annex M

MEMORANDUM

Letter from Baker & McKenzie, Solicitors, enclosing a copy of Mr Millar's affidavit

My Background

Clinical Research and Regulations

Batimastat

Marimastat

Zacutex (Lexipafant)

My Concerns with the Company's Strategy

The Cameron McKenna Report

CONFIDENTIALITY AGREEMENT

Paul Littlewood, British Biotech

MEMORANDUM

British Biotech plc

Cancer drug batimastat starts pivotal Phase III trials and new oral cancer drug, BB-2516, starts human clinical testing

Results for the three months ended 31 October 1994

Results for the three months ended 31 October 1994


Unaudited consolidated profit and loss account for the three months ended 31 October 1994

Unaudited consolidated profit and loss account for the three months ended 31 October 1994

Unaudited Consolidated Balance Sheet at 31 October 1994


Memo to file 3 February 1995

Memo to file (15-2-95)

Technical Note

Marimastat gives positive interim results in cancer patient trials Highlights

Marimastat gives positive interim results in cancer patient trials

Memorandum to Keith McCullagh from Andrew Millar

Memorandum to Keith McCullagh from Andrew Millar

Zacutex UK Phase III clinical data presented at American Gastroenterological Association

New appointments to support transition to an international operating business

Examination of Witness

DR ANDREW MILLAR, Former Head of Clinical Research, British Biotech, was examined.

Question Number

106 - 119

120 - 139

140 - 160

Supplementary Memorandum submitted by British Biotech plc

ANNEX 1

Appendix 1

ANNEX 2

Appendix I

Appendix II

Appendix III

ANNEX 2

ANNEX 3

ANNEX 4

Attachment Appendix


Attachment II

Attachment III

ANNEX 5

APPENDIX

ANNEX 1

Letter to the Chairman of the Committee from Dr Andrew Millar

---

---

Prepared 14 September 1998